Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750280 | 0.88 | TSHR (0.58) | TSHRSMN1; SMN2P2RX7HPGD | |
| SCHEMBL1751533 | 0.88 | TSHR (0.45) | TSHRSMN1; SMN2P2RX7HPGD | |
| SCHEMBL1751254 | 0.87 | P2RX7 (0.44) | TSHRSMN1; SMN2P2RX7HPGDTRPV1 | |
| SCHEMBL1751211 | 0.85 | EPHX2 (0.48) | TSHRSMN1; SMN2P2RX7HPGD | |
| SCHEMBL3092964 | 0.81 | HTR1A (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL3093509 | 0.81 | HTR7 (0.41) | TSHRSMN1; SMN2P2RX7 | |
| SCHEMBL3089010 | 0.79 | TSHR (0.43) | TSHRSMN1; SMN2TRPV1 | |
| SCHEMBL1750509 | 0.79 | KDM4E (0.46) | SMN1; SMN2HPGDTRPV1 | |
| SCHEMBL3074352 | 0.77 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL3088565 | 0.76 | PRMT5 (0.47) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | TSHR 1994/4885SMN1; SMN2 4441/4885P2RX7 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.